<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384341</url>
  </required_header>
  <id_info>
    <org_study_id>19PH224</org_study_id>
    <secondary_id>2019-A03358-49</secondary_id>
    <nct_id>NCT04384341</nct_id>
  </id_info>
  <brief_title>Haemophilia and Bone Loss - PHILEOS Study</brief_title>
  <acronym>PHILEOS</acronym>
  <official_title>Haemophilia and Bone Loss PHILEOS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemophilia is a rare bleeding disorder, characterized by factor VIII (HA) or factor IX (HB)&#xD;
      deficiency. The absence or the reduction of fVIII or fIX result in impaired thrombin&#xD;
      generation and clot formation, causing excessive bleeding (mainly haemarthrosis).&#xD;
      Osteoporosis is a systemic bone disease characterized by a low bone mineral density (BMD). A&#xD;
      decrease of mean BMD has been described in haemophilic patients compared to healthy controls&#xD;
      in several studies. So, osteoporosis could be an underestimated haemophilia-related&#xD;
      comorbidity. None of the following risk factors (reduced physical activity, joint damage,&#xD;
      vitamin D deficiency and /or hepatitis C virus (HCV) infection) has been retained as a cause&#xD;
      of osteoporosis in haemophilic patients. Another hypothesis is that bone loss could be&#xD;
      directly linked to fVIII or fIX and/or thrombin deficiency. The aim of this study is to&#xD;
      evaluate the prevalence of the bone loss in HA and B patients, according to the type, the&#xD;
      severity and the presence (or not) of a prophylactic treatment (depending on the age at which&#xD;
      it was began) and to compare it to a control population. The investigators will also evaluate&#xD;
      the relation between BMD and FVIII, fIX and thrombin potential.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and&#xD;
      advertisements.&#xD;
&#xD;
      Recruitment of haemophilic patients during a routine visit at the haemophilia centre.&#xD;
&#xD;
      Information of the subjects that the study requires a BMD measure for all and a blood&#xD;
      sampling for patients only.&#xD;
&#xD;
      After inclusion and exclusion criteria have been checked, the subject can sign the consent.&#xD;
&#xD;
      For all subjects, an appointment will be made for BMD measure. For patients and controls: BMD&#xD;
      will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar&#xD;
      spine (L2-L4) sites.&#xD;
&#xD;
      For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic&#xD;
      markers of bone remodelling will be measured centrally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Osteoporosis defined by a T-score &lt; -2.5 in severe haemophilic patients without prophylaxis and in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteoporosis defined by a T-score &lt; -2.5 in the different groups of haemophilic patients and in in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteopenia defined by a T-score &lt; -1 in the different groups of haemophilic patients and in in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (expressed as a T-score) in the different groups of haemophilic patients and in healthy subjects.</measure>
    <time_frame>During the procedure</time_frame>
    <description>Bone mineral densitometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal level of fVIII/fIX (expressed as an Ag level or as a %) or thrombin generation potential (expressed as an endogenous thrombin potential (ETP), nmol/min) and Bone mineral density (expressed as a T-score and Z-score)</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Blood test Relation between the basal level of fVIII or fIX (expressed as an Ag level or as a %) or the thrombin generation potential (expressed as an endogenous thrombin potential (ETP), nmol/min) and Bone mineral density (expressed as a T-score and Z-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers influencing bone metabolism in all haemophilic patients included</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Haemophilic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling Bone Densitometry (BMD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bone Densitometry (BMD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Bone densitometry (BMD)</intervention_name>
    <description>Recruitment of haemophilic patients during a routine visit at the haemophilia centre.&#xD;
Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.&#xD;
After inclusion and exclusion criteria have been checked, the subject can sign the consent.&#xD;
For all subjects, an appointment will be made for BMD measure.&#xD;
For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.&#xD;
Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements.</description>
    <arm_group_label>Haemophilic patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling for patients only</intervention_name>
    <description>For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.</description>
    <arm_group_label>Haemophilic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers :&#xD;
&#xD;
               -  Healthy men aged between 20 to 60 years old&#xD;
&#xD;
          -  Haemophilic Patients:&#xD;
&#xD;
               -  Haemophilia A and B patients, irrespective of the disease form (mild, moderate,&#xD;
                  severe with or without prophylaxis)&#xD;
&#xD;
               -  Haemophilic patients aged between 20 to 60 years old&#xD;
&#xD;
               -  Severe Haemophilia A patients with prophylaxis : last factor VIII injection more&#xD;
                  than 48 to 120 hours (depending on on the prophylactic treatment) prior blood&#xD;
                  sampling dedicated to the this research&#xD;
&#xD;
               -  Severe Haemophilia B patients : last factor IX injection more than 5 to 21 days&#xD;
                  (depending on the prophylactic treatment) prior blood sampling dedicated to the&#xD;
                  this research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers:&#xD;
&#xD;
               -  History of disease known to influence bone metabolism (hyperthyroidism,&#xD;
                  hyperparathyroidism, hypercorticism, hypogonadism, diseases that require&#xD;
                  long-term use of corticoids, â€¦)&#xD;
&#xD;
               -  Past or present treatment with any osteoporotic medication other than Vit D or&#xD;
                  Ca++&#xD;
&#xD;
               -  Presence of two total hip prostheses&#xD;
&#xD;
               -  HIV documented infection&#xD;
&#xD;
               -  HCV documented infection (in progress or cured) at cirrhotic stage&#xD;
&#xD;
          -  Haemophilic Patients:&#xD;
&#xD;
               -  Haemophilic patients with current or history of inhibitor anti-fVIII or anti-fIX&#xD;
                  (&gt;5 Bethesda Units)&#xD;
&#xD;
               -  Treatment with HEMLIBRA (Emicizumab). Unless it is possible to use a result of&#xD;
                  thrombin generation prior to this treatment and achieved with a residual rate not&#xD;
                  greater than or equal to 5%.&#xD;
&#xD;
               -  History of disease known to influence bone metabolism and not related to&#xD;
                  haemophilia (hyperthyroidism, hyperparathyroidism, hypercorticism, hypogonadism,&#xD;
                  diseases that require long-term use of corticoids, â€¦)&#xD;
&#xD;
               -  Past or present treatment with any anti-osteoporotic medication other than Vit D&#xD;
                  or Ca++&#xD;
&#xD;
               -  Presence of two total hip prostheses&#xD;
&#xD;
               -  HIV documented infection&#xD;
&#xD;
               -  HCV documented infection (in progress or cured) at cirrhotic stage&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte TARDY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte TARDY, MD</last_name>
    <phone>(0)477421877</phone>
    <email>brigitte.tardy@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)477120469</phone>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BELGIUM - Brussels</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cedric HERMANS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>SABINE CASTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia MESHEN-CETRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Brest Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BRIGITTE PAN-PETESCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yohann REPESSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GAUTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin GILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Metropole Savoie</name>
      <address>
        <city>ChambÃ©ry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ROMAIN JAILLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>VALERIE GAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal MEYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Cth Estaing Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>AURELIEN LEBRETON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria CACHEUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain MARQUES-VERDIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FABIENNE GENRE-VOLLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RAPHAEL MARLU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BENOIT POLACK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enkelejda HODAJ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antoine RAUCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie SUSEN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BÃ©nÃ©dicte WIBAUT-PEGNEAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu La Timone Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>CELINE FALAISE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HERVE CHAMBOST, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine POUYMAYOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Emmanuel MORANGE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Necker Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>LAURENT FRENZEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rennes Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>BENOIT GUILLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice LAINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie MAINGUY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de ROUEN</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PIERRE CHAMOUNI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie BARBAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie KOZYREFF-MEURICE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BRIGITTE TARDY</last_name>
    </contact>
    <investigator>
      <last_name>THIERRY THOMAS, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BRIGITTE TARDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg - HÃ´pital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DOMINIQUE DESPREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rose-Marie JAVIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROMANIA - Bucharest</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel CORIU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>fVIII</keyword>
  <keyword>fIX</keyword>
  <keyword>thrombin</keyword>
  <keyword>Haemophilia</keyword>
  <keyword>Hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

